(Total Views: 264)
Posted On: 04/07/2020 3:32:00 PM
Post# of 281
NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Launches AI Vaccine, Drug-Development Platform Targeting Coronaviruses, Acute Respiratory Syndromes
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently announced the launch of a new AI vaccine and drug development platform targeting coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS and SARS). An article discussing the company reads, “Through an interim operating agreement with Soluble Therapeutics, POAI believes the extensive experience utilizing artificial intelligence in its Helomics division to better understand and battle cancer will prove invaluable in the quest for solutions to the current global health crisis. Combining the HSC(TM) Technology with POAI’s predictive modeling platform is expected to create a new rapid AI discovery platform that quickly and cost effectively identifies potential therapeutic candidates. . . . ‘The combination of Soluble Therapeutics’ technology with Predictive Oncology’s AI capability has the potential to rapidly optimize formulations thereby accelerating the early phase of protein therapeutic development,’ HSC(TM) co-inventor Dr. Larry DeLucas stated in a news release (http://nnw.fm/3uS2j). DeLucas, who flew aboard NASA Space Shuttle mission STS–50 as a payload specialist, is now the director of the Center for Structural Biology at University of Alabama School of Medicine.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently announced the launch of a new AI vaccine and drug development platform targeting coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS and SARS). An article discussing the company reads, “Through an interim operating agreement with Soluble Therapeutics, POAI believes the extensive experience utilizing artificial intelligence in its Helomics division to better understand and battle cancer will prove invaluable in the quest for solutions to the current global health crisis. Combining the HSC(TM) Technology with POAI’s predictive modeling platform is expected to create a new rapid AI discovery platform that quickly and cost effectively identifies potential therapeutic candidates. . . . ‘The combination of Soluble Therapeutics’ technology with Predictive Oncology’s AI capability has the potential to rapidly optimize formulations thereby accelerating the early phase of protein therapeutic development,’ HSC(TM) co-inventor Dr. Larry DeLucas stated in a news release (http://nnw.fm/3uS2j). DeLucas, who flew aboard NASA Space Shuttle mission STS–50 as a payload specialist, is now the director of the Center for Structural Biology at University of Alabama School of Medicine.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
